Table 1.
Baseline Clinicopathological Characteristics of Study Subjects
| Initial characteristics | Total (n=176) | LO group (n=96) | HI group (n=80) | p-Value |
|---|---|---|---|---|
| Age (years) | 50.1±9.0 | 51.3±8.4 | 48.7±9.6 | 0.92 |
| Sex | 0.46 | |||
| Men | 7 (4.0%) | 5 (5.2%) | 2 (2.5%) | |
| Women | 169 (96.0%) | 91 (94.8%) | 78 (97.5%) | |
| Pathology | 0.21 | |||
| PTC | 173 (98.3%) | 95 (99.0%) | 78 (97.5%) | |
| FV-PTC | 2 (1.1%) | 0 (0%) | 2 (2.5%) | |
| FTC | 1 (0.6%) | 1 (1.0%) | 0 (0%) | |
| Tumor size (cm) | 1.1±0.5 | 1.0±0.4 | 1.3±0.4 | <0.001 |
| ≤1 | 85 (48.3%) | 61 (63.5%) | 24 (30.0%) | |
| >1–2 | 91 (51.7%) | 35 (36.5%) | 56 (70.0%) | |
| AJCC TNM stage (2002) | 0.12 | |||
| Stage I | 45 (25.6%) | 20 (20.8%) | 25 (31.2%) | |
| Stage III | 131 (74.4%) | 76 (79.2%) | 55 (68.8%) | |
| Multifocality | 64 (36.4%) | 35 (36.5%) | 29 (36.2%) | 0.99 |
| Bilaterality | 46 (26.1%) | 24 (25.0%) | 22 (27.5%) | 0.73 |
| Lymphovascular invasion | 2 (9.7%) | 1 (1.0%) | 1 (1.3%) | 0.99 |
| No. of removed LNs | 10.5±7.1 | 10.3±7.6 | 10.7±6.7 | 0.80 |
| Serum Tg level at ablation | 1.0±2.4 | 0.7±1.5 | 1.4±3.2 | 0.09 |
PTC, papillary thyroid carcinoma; FV-PTC, follicular variant PTC; FTC, follicular thyroid carcinoma; LNs, lymph nodes; Tg, thyroglobulin.